Raloxifene
Raloxifene (Evista) is a selective estrogen receptor modulator (SERM). It binds to estrogen receptors and blocks bone resorption, while not stimulating growth in endometrium or breast tissue. It is FDA indicated for the prevention and treatment of osteoporosis. The Multiple Outcomes of Raloxifene Trial (MORE) showed a statistically significant reduction in vertebral fractures only. Raloxifene is associated with an increase risk of deep venous thrombosis and a reduction in breast cancer incidence. Use is associated with an increase in intensity and frequency of hot flashes.
Raloxifene (Evista): 60mg, po, daily